Fulton Bank N.A. grew its stake in Roche Holding AG (OTCMKTS:RHHBY) by 12.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,089 shares of the company’s stock after purchasing an additional 2,543 shares during the period. Fulton Bank N.A.’s holdings in Roche were worth $937,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors also recently bought and sold shares of RHHBY. Accel Wealth Management purchased a new stake in shares of Roche in the fourth quarter valued at about $33,000. Crescent Capital Consulting LLC purchased a new stake in shares of Roche in the 4th quarter valued at approximately $44,000. Bartlett & Co. LLC increased its holdings in shares of Roche by 62.0% during the 4th quarter. Bartlett & Co. LLC now owns 1,928 shares of the company’s stock worth $85,000 after buying an additional 738 shares during the last quarter. Colony Group LLC purchased a new stake in shares of Roche during the 3rd quarter valued at approximately $214,000. Finally, Rothschild Investment Corp IL lifted its holdings in Roche by 16.9% in the fourth quarter. Rothschild Investment Corp IL now owns 6,900 shares of the company’s stock valued at $302,000 after acquiring an additional 1,000 shares during the last quarter. 0.32% of the stock is owned by hedge funds and other institutional investors.
RHHBY has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft began coverage on Roche in a research report on Friday, January 15th. They issued a “hold” rating on the stock. Berenberg Bank reaffirmed a “hold” rating on shares of Roche in a research report on Thursday, February 25th. Barclays reiterated an “overweight” rating on shares of Roche in a research report on Friday, January 22nd. UBS Group lowered shares of Roche from a “buy” rating to a “neutral” rating in a report on Wednesday, February 17th. Finally, Jefferies Financial Group cut shares of Roche to a “hold” rating in a research report on Tuesday, March 16th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $48.00.
The firm also recently declared a dividend, which was paid on Monday, March 29th. Shareholders of record on Friday, March 19th were paid a $1.2782 dividend. The ex-dividend date of this dividend was Thursday, March 18th. This represents a dividend yield of 3.11%. Roche’s dividend payout ratio (DPR) is 30.31%.
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation.
Recommended Story: History of the Euro STOXX 50 Index
Want to see what other hedge funds are holding RHHBY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roche Holding AG (OTCMKTS:RHHBY).
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.